Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Leerink Partnrs issued their Q1 2026 EPS estimates for Sarepta Therapeutics in a research note issued to investors on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz forecasts that the biotechnology company will post earnings per share of $0.88 for the quarter. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $1.07 EPS.

SRPT has been the subject of several other research reports. The Goldman Sachs Group cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating and set a $29.00 target price for the company. in a report on Tuesday, June 17th. Wells Fargo & Company reduced their price target on shares of Sarepta Therapeutics from $75.00 to $65.00 and set an “overweight” rating for the company in a research report on Thursday. Wolfe Research initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, June 17th. They set a “peer perform” rating for the company. Cantor Fitzgerald reiterated a “neutral” rating on shares of Sarepta Therapeutics in a research note on Monday, June 16th. Finally, Mizuho decreased their price target on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, June 18th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $56.50.

Sarepta Therapeutics Stock Down 36.0%

Shares of Sarepta Therapeutics stock opened at $14.07 on Friday. Sarepta Therapeutics has a 52-week low of $12.81 and a 52-week high of $150.48. The company has a 50 day moving average of $28.42 and a 200 day moving average of $67.97. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $1.38 billion, a P/E ratio of -5.23 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter last year, the firm posted $0.73 EPS. The company’s revenue for the quarter was up 80.2% on a year-over-year basis.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the company. Capital International Investors boosted its position in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Norges Bank acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $126,315,000. Assenagon Asset Management S.A. boosted its position in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company’s stock worth $45,477,000 after acquiring an additional 580,123 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock worth $168,907,000 after acquiring an additional 577,848 shares during the last quarter. Finally, EcoR1 Capital LLC boosted its position in shares of Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock worth $82,480,000 after acquiring an additional 522,386 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.